Published in TB and Outbreaks Week, April 16th, 2002
Under terms of the agreement, the Army will perform various tests and laboratory assays to determine if Antex's lead antibiotic and other proprietary compounds are potent against fighting anthrax infections and diseases caused by Bacillus anthracis.
The company's lead antibiotic is a therapeutic initially targeted for skin and soft tissue infections. While this antibiotic is being developed for the treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week